On October 6, 2020 Maze Therapeutics, a company focused on translating genetic insights into new medicines, reported that Sarah Noonberg, M.D., Ph.D., has been appointed as the company’s chief medical officer (Press release, Maze Therapeutics, OCT 6, 2020, View Source [SID1234568163]). Dr. Noonberg brings significant industry and clinical experience to Maze as the company works to advance its pipeline.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Sarah is an exceptional leader who has helped guide multiple companies through various stages of clinical development and commercialization, and we are thrilled to welcome her to the Maze team," said Jason Coloma, Ph.D., chief executive officer of Maze. "We have been working hard to build an exciting pipeline of potential therapeutics based on targets generated through our platform, and Sarah’s broad experience leading programs from translational research through commercialization for both rare and common diseases will be instrumental. As we take important steps toward entering the clinic and defining our development strategies, we could not be more excited to have her on board and for the future of Maze."
Dr. Noonberg is a board-certified physician-scientist with broad expertise and a proven track record in global clinical development and corporate strategy. Dr. Noonberg joins Maze from prior roles as chief medical officer of Nohla Therapeutics and Prothena Biosciences, and earlier, head of global clinical development at BioMarin Pharmaceutical, Inc., where she advanced a broad portfolio including cerliponase alfa (Brineura) for CLN2 disease, pegvaliase (Palynziq) for phenylketonuria, and gene therapy for hemophilia A. Prior to BioMarin, she was senior vice president at Medivation leading translational and early development activities as well as late-stage development of enzalutamide (XTANDI) for advanced prostate cancer. Dr. Noonberg currently serves on the board of directors of Protagonist Therapeutics and Neoleukin Therapeutics. She holds an M.D. from the University of California, San Francisco, a Ph.D. in bioengineering from the University of California, Berkley, and a B.S. in engineering science from Dartmouth College.
"Maze has assembled all of the key ingredients to produce a diverse pipeline of meaningful therapeutics that could significantly impact the treatment of patients with a broad range of diseases," said Dr. Noonberg. "I have been impressed by the company’s approach of leveraging human genetics insights and functional genomics to build an exceptional platform. I look forward to helping lead Maze’s programs through development, and ultimately, bringing them to patients in need."